Business
PRTC Publishes Research on Unmet IPF Patient Needs
PRTC Publishes Research on Unmet IPF Patient Needs.
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n9 May 2025\nPureTech Health plc\n \nPureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)\n \nResearch conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF\n \nFindings highlight the profound physical, emotional, and psychosocial burden of IPF and underscore urgent need for enhanced education, streamlined diagnosis, patient-focused treatment plans, and more effective therapies\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the publication of new research in BMC Pulmonary Medicine that provides a comprehensive view into the lived experiences of people with idiopathic pulmonary fibrosis (IPF). Conducted in collaboration with Tejaswini Kulkarni, MD, MPH, from the University of Alabama at Birmingham, Lisa Lancaster, MD, from Vanderbilt University Medical Center, and Jessica Shore, RN, PhD, from the Pulmonary Fibrosis Foundation (PFF), the study identifies critical barriers to treatment, opportunities for improved community engagement, and the need for patient-centered approaches in the development of new therapeutics. Initial findings from this research were presented at the 2023 Pulmonary Fibrosis Foundation Summit, the American Thoracic Society 2024 International Conference, and the CHEST 2024 Annual Meeting.\n \n\"It's remarkable that despite the availability of approved therapies, antifibrotic uptake remains persistently low. This lack of engagement reflects not just clinical barriers but fundamental gaps in understanding the experiences of people living with IPF, and we wanted to highlight their voices in this study,\" said Camilla Graham, MD, MPH, Senior Vice President of Medical Affairs at PureTech and lead author of the study. \"By integrating the perspectives of people with IPF into every stage of diagnosis, disease management, education, and clinical development, we have a real opportunity to shift the paradigm for IPF care to one that is more empathetic, effective, and aligned with the realities of living with this serious ...